Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Caribou Biosciences (Nasdaq: CRBU) announced that president and CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35 p.m. ET in New York.
The live and archived webcasts will be accessible via the Events page on Caribou’s website for at least 30 days.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Conference participation | Neutral | +0.9% | Announced fireside chat at H.C. Wainwright BioConnect investor conference. |
| May 12 | Clinical presentations | Neutral | +0.0% | Planned EHA oral presentations on vispa-cel and CB-011 phase 1 data. |
| May 07 | Earnings and update | Positive | +3.2% | Q1 2026 results plus FDA alignment on ANTLER-3 and RMAT for CB-011. |
| May 05 | Conference participation | Neutral | +1.0% | CEO scheduled for fireside chat at BofA Securities health care conference. |
| Mar 31 | Regulatory designation | Positive | +10.5% | FDA granted RMAT designation to CB-011 based on phase 1 data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent CRBU headlines, from conference participation to FDA designations and earnings updates, have generally coincided with flat-to-positive next-day moves, including a notably strong reaction to RMAT designation news.
Over the last few months, CRBU has mixed routine conference participation updates with more material clinical and regulatory milestones. Events on May 5 and May 13, 2026 announced fireside chats at major healthcare conferences, each followed by modestly positive reactions. Earnings on May 7, 2026 combined financial results with clinical progress and drew a stronger positive move. The March 31, 2026 RMAT designation for CB-011 produced the largest gain, underscoring investor focus on de-risking milestones in the CAR-T pipeline.
Key Terms
crispr genome-editing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35pm ET in New York.
For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.
About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the company @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
investor.relations@cariboubio.com
media@cariboubio.com
